Troy Ignezli serves as Chief Financial Officer at Rapport Therapeutics Inc., a clinical-stage biotechnology company pioneering precision medicines for neurological disorders. With over 25 years of experience in the life sciences industry, Ignezli brings a proven track record of driving financial strategy and growth for both public and private biotech firms. He oversees all financial operations at Rapport, including capital raising, investor relations, accounting, and strategic planning, playing a pivotal role in advancing the company's RAPPORT™ platform and its lead candidate, RP-001, through clinical development. Prior to joining Rapport in 2023, Ignezli was CFO at Aadi Bioscience, where he led the company's successful initial public offering on Nasdaq in 2021, raising over $170 million, and managed subsequent business development initiatives. Previously, as Senior Vice President of Finance at Reata Pharmaceuticals, he spearheaded the firm's IPO and navigated its $7.3 billion acquisition by Biogen in 2023. His earlier career includes key finance leadership roles at Relypsa (acquired by Galapagos), Onyx Pharmaceuticals (acquired by Amgen), and Genentech, complemented by his time as a consultant at Deloitte, honing his expertise in complex financings, M&A, and regulatory compliance. Ignezli's achievements include orchestrating multiple high-profile transactions totaling billions in value, positioning him as a strategic leader adept at scaling biotech enterprises amid dynamic market conditions. A Certified Public Accountant, he holds a B.S. in Accounting from San Jose State University and resides in the San Francisco Bay Area, where he continues to champion financial discipline and innovation at Rapport Therapeutics.